Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04155 (
pS2
)
1,234
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Nuclear receptor-mediated gene expression is regulated by corepressors and coactivators. In this study we demonstrate that
prohibitin
(
PHB
), a potential tumor suppressor, functions as a potent transcriptional corepressor for estrogen receptor alpha (ERalpha). Overexpression of
PHB
inhibits ERalpha transcriptional activity, whereas depletion of endogenous
PHB
increases the expression of ERalpha target genes in MCF-7 breast cancer cells. Chromatin immunoprecipitation experiments demonstrate that
PHB
is associated with the estrogen-regulated
pS2
promoter in the absence of hormone and dissociates after estradiol treatment. We demonstrate that
PHB
interacts with the repressor of estrogen receptor activity (REA), a protein related to
PHB
, to form heteromers and enhance the protein stability of both corepressors. Interestingly, the corepressor activity of
PHB
is cross-squelched by the coexpression of REA (and vice versa), suggesting that
PHB
and REA repress transcription only when they are not paired. We further demonstrate that coiled-coil domains located in the middle of
PHB
and REA are responsible for their heteromerization, stabilization, and cross-squelching actions. Finally, ablation of
PHB
function in the mouse results in early embryonic lethality, whereas mice heterozygous for the
PHB
null allele exhibit a hyperproliferative mammary gland phenotype. Our results indicate that
PHB
functions as a transcriptional corepressor for ERalpha in vitro and in vivo, and that its heteromerization with REA acts as a novel mechanism to limit its corepressor activity.
...
PMID:A repressive role for prohibitin in estrogen signaling. 1793 4